GSK's B7-H3 ADC delivers first Phase III survival win in relapsed lung cancer
UK pharma major GSK (LSE: GSK) has set out full survival data for risvutatug rezetecan, its B7-H3 targeted antibody-drug conjugate (ADC), in what it says are the first Phase III results showing a survival gain for the target class in any tumor type. The trial was run in China by partner Hansoh Pharmaceutical Group (HKEX: 3692).
In the ARTEMIS-008 study, presented at the World Conference on Lung Cancer in Seoul, the drug cut the risk of death by 54% against topotecan in patients whose small cell lung cancer (SCLC) had progressed after platinum-based first-line treatment. Median overall survival (OS) was 18.5 months versus 10.3 months for topotecan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze